Editorial: Antidepressants to the Rescue in Severe Mood Dysregulation and Disruptive Mood Dysregulation Disorder?
- PMID: 31128267
- DOI: 10.1016/j.jaac.2019.05.016
Editorial: Antidepressants to the Rescue in Severe Mood Dysregulation and Disruptive Mood Dysregulation Disorder?
Abstract
Children with irritability and outbursts pose a serous therapeutic problem. Many of them have attention-deficit/hyperactivity disorder (ADHD) with emotion dysregulation, which is sometimes captured in the diagnosis of disruptive mood dysregulation disorder (DMDD). Some follow-up data find a connection between DMDD and depression and anxiety in adults. This prompted Towbin and colleagues1 to launch a trial where children (ages 7-17) with DMDD were treated first with methylphenidate (MPH) and then randomized to citalopram (CTP) or placebo over 8 weeks. The response to CTP was complicated by lack of specific measures of both irritable mood and severity of outbursts. Future studies should include standardized and normed parent and teacher measures of both externalizing and internalizing behavior as well as irritability specific measures rating how the child feels. Studies also need better measures of the actual outbursts-not just their frequency but how agitated or aggressive the child gets during an outburst (ie, what the child does) and how long the outbursts last. Measuring DMDD on inpatient units is especially complicated because of the therapeutic nature of the setting. Further work is needed with much larger samples to identify who improves with the treatment, exactly which domains of psychopathology improve and by how much. Finally, It is also critical to conduct longer-term trials to determine the stability of the response beyond 8 weeks.
Copyright © 2019 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Comment on
-
A Double-Blind Randomized Placebo-Controlled Trial of Citalopram Adjunctive to Stimulant Medication in Youth With Chronic Severe Irritability.J Am Acad Child Adolesc Psychiatry. 2020 Mar;59(3):350-361. doi: 10.1016/j.jaac.2019.05.015. Epub 2019 May 23. J Am Acad Child Adolesc Psychiatry. 2020. PMID: 31128268 Free PMC article. Clinical Trial.
Similar articles
-
Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.J Child Adolesc Psychopharmacol. 2018 Jun;28(5):298-305. doi: 10.1089/cap.2017.0124. Epub 2018 Apr 30. J Child Adolesc Psychopharmacol. 2018. PMID: 29708762 Free PMC article.
-
Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.J Child Adolesc Psychopharmacol. 2018 Dec;28(10):682-689. doi: 10.1089/cap.2018.0068. Epub 2018 Aug 27. J Child Adolesc Psychopharmacol. 2018. PMID: 30148656 Clinical Trial.
-
Disruptive Mood Dysregulation Disorder Symptoms and Association with Oppositional Defiant and Other Disorders in a General Population Child Sample.J Child Adolesc Psychopharmacol. 2016 Mar;26(2):101-6. doi: 10.1089/cap.2015.0074. Epub 2016 Jan 8. J Child Adolesc Psychopharmacol. 2016. PMID: 26745442 Free PMC article.
-
Disruptive mood dysregulation disorder: a new diagnostic approach to chronic irritability in youth.Am J Psychiatry. 2014 Sep;171(9):918-24. doi: 10.1176/appi.ajp.2014.13101301. Am J Psychiatry. 2014. PMID: 25178749 Free PMC article. Review.
-
Disruptive Mood Dysregulation Disorder (DMDD): An RDoC perspective.J Affect Disord. 2017 Jul;216:117-122. doi: 10.1016/j.jad.2016.08.007. Epub 2016 Aug 13. J Affect Disord. 2017. PMID: 27554606 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources